Posted by Michael Wonder on 06 Nov 2024
Acadia Pharmaceuticals enters into an agreement to sell its rare paediatric disease priority review voucher for $150 million
5 November 2024 - Acadia Pharmaceuticals today announced that it entered into a definitive asset purchase agreement to sell its rare paediatric disease priority review voucher for $150 million upon the closing of the transaction.
Acadia was granted the voucher in March 2023 following approval by the US FDA of Daybue (trofinetide) for the treatment of Rett syndrome.
